

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **January 9, 2013**

**BioTime, Inc.**

(Exact name of registrant as specified in its charter)

**California**

(State or other jurisdiction  
of incorporation)

**1-12830**

(Commission File Number)

**94-3127919**

(IRS Employer  
Identification No.)

**1301 Harbor Bay Parkway  
Alameda, California 94502**

(Address of principal executive offices)

**(510) 521-3390**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

## Section 7 - Regulation FD

### Item 7.01 - Regulation FD Disclosure

On January 9, 2013, we issued the press release filed as Exhibit 99.1, which is incorporated by reference.

## Section 9 - Financial Statements and Exhibits

### Item 9.01 - Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated January 9, 2013.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOTIME, INC.**

Date: January 9, 2013

By: /s/ Michael D. West  
Chief Executive Officer

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated January 9, 2013.

**LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02**

ALAMEDA, Calif.--(BUSINESS WIRE)--January 9, 2013--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of *MalaCards* version 1.02 on January 7. The new release is available at [www.malacards.org](http://www.malacards.org). *MalaCards* is a new database of human diseases and their annotations that is modeled on the architecture and richness of the popular *GeneCards*<sup>®</sup> database of human genes. LifeMap Sciences holds the exclusive worldwide license to market *MalaCards* and *GeneCards*<sup>®</sup> from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. *MalaCards* contains computerized “cards” classifying information relating to a wide array of human diseases. This novel research tool will aid researchers in studying the roles of genes and cells in disease processes. *MalaCards* and *GeneCards*<sup>®</sup> were developed, and are continuously enhanced by ongoing research, by the bioinformatics team at the Department of Molecular Genetics at the Weizmann Institute of Science in Israel, with Professor Doron Lancet, head of the Crown Human Genome Center, and team leader Marilyn Safran.

The recent release includes enhanced ontology-based accounts of drug-disease associations, considerably improved portrayal of inter-disease relationships, including graphical representation of disease networks, *MalaCards*-unique disease summaries and the augmentation of anatomical context and related stem-cell-based therapeutic approaches.

“This new release further underlines how enhanced data resource integration can lead to a considerably improved research tool,” said Professor Doron Lancet, Ph.D., head of the Crown Human Genome Center at the Weizmann Institute of Science.

“*MalaCards* version 1.02 offers significant improvements for our academic and commercial users,” stated Yaron Guan-Golan, LifeMap Sciences’ Head of Marketing. “The introduction of industry standard identifiers like ICD9 and MeSh will significantly improve enterprise integration and data mining capabilities. Coupled with our new data sources, including LifeMap Sciences’ own *LifeMap Discovery*<sup>™</sup>, we believe that *MalaCards* is becoming an essential companion for disease researchers worldwide.”

***About LifeMap Sciences, Inc.***

LifeMap Sciences’ ([www.lifemapsc.com](http://www.lifemapsc.com)) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem-cell research. This platform includes *GeneCards*<sup>®</sup>, the leading human gene database; *LifeMap Discovery*<sup>™</sup>, the database of embryonic development, stem cell research and regenerative medicine; and *MalaCards*, the human disease database. LifeMap Sciences also markets *PanDaTox*, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.

---

In addition to database offerings, LifeMap Sciences is BioTime's principal marketing subsidiary for research products, including *PureStem*<sup>™</sup> human progenitor cell lines, GMP human embryonic stem (hES) cell lines, *Espan*<sup>™</sup> growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its *LifeMap BioReagents*<sup>™</sup> portal. LifeMap Sciences utilizes its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap's scientists utilize LifeMap's proprietary platform, including *LifeMap Discovery*<sup>™</sup>, its stem cell database along with the *GeneCards*<sup>®</sup> and *MalaCards* integrated database suite, to aid in the development of BioTime's proprietary *PureStem*<sup>™</sup> human progenitor cell lines into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. The *LifeMap Discovery*<sup>™</sup> platform will be used to select the progenitor cell lines that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases.

### ***About BioTime, Inc.***

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary *PureStem*<sup>™</sup> cell lines, *HyStem*<sup>®</sup> hydrogels, culture media, and differentiation kits. BioTime is developing *Renovia*<sup>™</sup> (formerly known as *HyStem*<sup>®</sup>-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product *PanC-Dx*<sup>™</sup> currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets *GeneCards*<sup>®</sup>, the leading human gene database, and is developing an integrated database suite to complement *GeneCards*<sup>®</sup> that will also include the *LifeMap Discovery*<sup>™</sup> database of embryonic development, stem cell research and regenerative medicine, and *MalaCards*, the human disease database. LifeMap will also market BioTime research products. BioTime Acquisition Corporation ("BAC") is a subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment. BioTime's lead product, *Hextend*<sup>®</sup>, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at [www.biotimeinc.com](http://www.biotimeinc.com).

---

## ***About the Weizmann Institute of Science and GeneCards***

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,700 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and scientific, technical and administrative staff. In addition, visiting scientists and their families – over 500 from 35 countries in 2010, are regularly hosted at the Institute. The Institute was founded in 1934 following a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who envisioned the establishment of a world-class scientific research center in Israel, and later also became the first President of the State of Israel. Weizmann Institute's Feinberg Graduate School was established in 1958, where about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the Institute's 18 departments, which are grouped into five faculties: Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer Science. The Institute's commercial arm, Yeda Research and Development Co. was the first company of its kind in Israel, and is currently one of the most successful worldwide. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment. Particular excellence in bioinformatics and systems biology is manifested, among others, in the GeneCards project, initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by Marilyn Safran continuously innovates and keeps GeneCards as a world-top human gene compendium, automatically mining and integrating 100 world-wide web resources.

### ***Forward-Looking Statements***

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:

<http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts>

#### **CONTACT:**

BioTime, Inc.

Peter Garcia, 510-521-3390, ext. 367

Chief Financial Officer

[pgarcia@biotimemail.com](mailto:pgarcia@biotimemail.com)

Judith Segall, 510-521-3390, ext. 301

[jsegall@biotimemail.com](mailto:jsegall@biotimemail.com)

or

LifeMap Sciences, Inc.

Kenneth Elsner, 781-826-7719

COO

[ke@lifemapsc.com](mailto:ke@lifemapsc.com)